Copyright
©The Author(s) 2024.
World J Diabetes. Aug 15, 2024; 15(8): 1793-1801
Published online Aug 15, 2024. doi: 10.4239/wjd.v15.i8.1793
Published online Aug 15, 2024. doi: 10.4239/wjd.v15.i8.1793
Figure 4 Teplizumab vs placebo.
A: Pooled odds ratio (OR) of total adverse effects in teplizumab vs placebo; B: Pooled OR of gastrointestinal adverse effects in teplizumab vs placebo; C: OR of dermatological adverse effects in teplizumab vs placebo; D: OR of lymphopenia in teplizumab vs placebo.
- Citation: Buddhavarapu V, Dhillon G, Grewal H, Sharma P, Kashyap R, Surani S. Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review. World J Diabetes 2024; 15(8): 1793-1801
- URL: https://www.wjgnet.com/1948-9358/full/v15/i8/1793.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i8.1793